Idaho medicaid drug utilization review program l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 69

Idaho Medicaid Drug Utilization Review Program PowerPoint PPT Presentation


  • 178 Views
  • Uploaded on
  • Presentation posted in: General

Idaho Medicaid Drug Utilization Review Program . 14 April 2011. Follow-up to Previous Reviews. Long Acting Beta Agonist Inhalers Lack of Prior Controller Use Long Acting Beta Agonist Inhalers with High Rescue Inhaler Use Fentanyl Patch Frequency < 72 Hours.

Download Presentation

Idaho Medicaid Drug Utilization Review Program

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Idaho medicaid drug utilization review program l.jpg

Idaho Medicaid Drug Utilization Review Program

14 April 2011


Follow up to previous reviews l.jpg

Follow-up to Previous Reviews

  • Long Acting Beta Agonist Inhalers

    • Lack of Prior Controller Use

  • Long Acting Beta Agonist Inhalers with High Rescue Inhaler Use

  • Fentanyl Patch Frequency < 72 Hours


Long acting beta agonist inhalers lack of controller use l.jpg

Long Acting Beta Agonist Inhalers: Lack of Controller Use

  • Letters sent if patient had at least one fill of a LABA during the 3 month period that ended on 9/30/2010. History was evaluated for long term continuous use of a LABA and lack of a controller medication if applicable.

    Results:

  • 150 patient profiles were evaluated.

  • Letters were sent to 32 prescribers about 30 patients on 12/16/2010 (21.3% lettering rate.)

  • As of 3/31/2011, 9 responses have been received (28% response rate.)

  • See packet for copy of the letter .


Long acting beta agonist inhalers lack of controller use response detail as of 3 31 2011 l.jpg

Long Acting Beta Agonist Inhalers: Lack of Controller Use: Response detail as of 3/31/2011:

  • Note that providers may choose more than one selection per response.

    • Reviewed and do not believe adjustment is needed3

    • Reviewed and have or will modify the treatment2

    • Information clinically useful: plan to monitor2

    • I will use this information in the care of future pts2

    • No longer my patient1

    • My patient, but I did not prescribe this2

    • Somewhat useful to my practice4

    • Not useful to my practice2

    • Information appears to be incorrect1


Long acting beta agonist inhalers with high rescue inhaler use l.jpg

Long Acting Beta Agonist Inhalers with High Rescue Inhaler Use

  • Patients were selected for evaluation if they had at least one fill of a LABA during the 6 month period and at least 2 fills for a SABA in the period that ended on 10/30/2010.

  • 208 patient profiles were evaluated.

  • Letters were sent to 399 prescribers about 102 patients on 12/28/2010 (192% lettering rate.)

  • As of 3/31/2011, 119 responses have been received (30% response rate.)

  • See packet for copy of the letter.


Saba overuse in laba patients response detail as of 1 1 2011 l.jpg

SABA overuse in LABA patients: Response detail as of 1/1/2011:

  • Note that providers may choose more than one selection per response.

    • Reviewed and do not believe adjustment is needed21

    • Reviewed and have or will modify the treatment23

    • Attempted to modify therapy unsuccessfully7

    • Information clinically useful: plan to monitor25

    • I will use this information in the care of future pts8

    • Not my patient8

    • Previously saw this pt, but no longer in my care14

    • My patient, but I did not prescribe this31

    • Under my care, but have not seen recently9

    • Extremely useful to my practice8

    • Very useful to my practice20

    • Somewhat useful to my practice11

    • Not useful to my practice1o

    • Information appears to be incorrect2

    • Will discontinue medication1

    • Will change dose6


Fentanyl topical patch duragesic frequency of administration l.jpg

Fentanyl Topical Patch (Duragesic®): Frequency of Administration

Patients were selected for evaluation if they received more than 10 patches in a 30 day period during the 3 month period that ended on 11/30/2010.

291 patient profiles were evaluated.

Letters were sent to 60 prescribers about 44 patients on 12/28/2010 (21% lettering rate.)

As of 3/31/2011, 29 responses have been received (48 % response rate.)

See packet for copy of the letter.


Fentanyl patch frequency of administration response detail as of 1 1 2011 l.jpg

Fentanyl Patch Frequency of Administration: Response detail as of 1/1/2011:

  • Note that providers may choose more than one selection per response.

    • Reviewed and do not believe adjustment is needed19

    • Reviewed and have or will modify the treatment4

    • Attempted to modify therapy unsuccessfully4

    • Information clinically useful: plan to monitor2

    • Previously saw this pt, but no longer in my care3

    • Very useful to my practice2

    • Somewhat useful to my practice2

    • Will change dose1


Low dose quetiapine utilization l.jpg

Quetiapine (Seroquel® ) is an atypical antipsychotic with the following indications and recommended doses

Low Dose Quetiapine Utilization

* Clinical studies indicate that the antipsychotic effect occurs in the range of 600-800mg


Seroquel dosage l.jpg

Seroquel® Dosage

Dosage Strengths Available: 25mg, 50mg, 100mg, 200mg, 300mg, 400mg

Legitimate Use of Lower Strengths

  • Initial dose titration (approximately 5 days)

  • Dose adjustments

  • Dose individualization not covered by single strength tablets

    Use of Concern

  • Off label use for insomnia


Use of quetiapine for insomnia l.jpg

Use of Quetiapine for Insomnia

  • Used at doses considered sub-therapeutic for schizophrenia or bipolar disorder

  • Used for insomnia in patients who do not have co-morbid psychosis

  • Not FDA-Approved

  • Not supported by available clinical evidence

  • Exposure of patients to adverse metabolic effects including weight gain, hyperglycemia, overt diabetes and adverse lipid profiles

  • More costly than traditional hypnotics


Idaho medicaid dur study april 2008 l.jpg

Idaho Medicaid DUR Study April 2008

  • Reviewed Medicaid Claims 1/2006 thru 12/2007

  • Identified patients using all AAPs at a low dose without schizophrenia, bipolar disorder or childhood psychosis/developmental disorders

  • Low dose quetiapine defined as < 300 mg/day

  • 395 patients identified as being on low dose quetiapine without above designated diagnoses (10% of claims)

  • Educational leaflets distributed


Current utilization of low dose quetiapine l.jpg

Current Utilization of Low Dose Quetiapine

  • Evaluated number of recipients receiving quetiapine 50 mg/day or less for more than 30 days for time period of 4/1/10-3/31/11

  • 130 recipients receiving <25 mg daily

  • 525 recipients receiving >25mg & <50mg daily

  • Total cost was $378,994

  • 28% of all quetiapine patients were getting <50mg/day


Current utilization of low dose quetiapine by gender l.jpg

Current Utilization of Low Dose Quetiapine by Gender

Information based on Idaho Medicaid Claims most recent 12 months (4/1/10-3/31/11)


Current utilization of low dose quetiapine by age l.jpg

Current Utilization of Low Dose Quetiapine by Age


Proposal for pa criteria l.jpg

Proposal for PA Criteria

  • Quetiapine cumulative daily doses of < 100 mg will be automatically approved only for new starts for a maximum of 15 days. (add all dosage strengths)

  • All other uses including dose titration in existing patients will require prior authorization review


Current intervention outcome studies l.jpg

Current Intervention/Outcome Studies

  • Tramadol with SSRI’s or SNRI’s

    • Potential for Serotonin Syndrome

  • Thiazolidinedione (TZD) Safety

  • Proton Pump Inhibitors

    • Long Term Continuous Use


Serotonin syndrome l.jpg

Serotonin Syndrome

  • Potentially life-threatening reaction to an elevation of serotonin in the body. Agents that block the reuptake of serotonin, slow breakdown, or increase release can contribute to development of the syndrome.

  • Resolves quickly with appropriate treatment, including discontinuation of related medication.

  • Frequently undiagnosed due to lack of awareness and the wide range of medications that can cause Serotonin Syndrome.


Tramadol with ssri s or snri s potential for serotonin syndrome l.jpg

Tramadol with SSRI’s or SNRI’s: Potential for Serotonin Syndrome

  • Patients were selected if they had more than one tramadol fill, at least a 30 day overlap with the SSRI or SNRI, and had both a tramadol and an antidepressant claim within the most recent six weeks of data.

  • 179 patient profiles were evaluated.

  • Letters were sent to 174 prescribers about 94 patients on 2/21/2011.

  • Only prescribers of tramadol, SSRI, or SNRI received letters.

  • As of 3/31/2011, 39 responses have been received (22% response rate.)

  • See packet for copy of the letter and Serotonin Syndrome Informational sheet.


  • Tramadol with ssri s or snri s potential for serotonin syndrome20 l.jpg

    Tramadol with SSRI’s or SNRI’s: Potential for Serotonin Syndrome


    Tramadol with ssri s or snri s potential for serotonin syndrome21 l.jpg

    Tramadol with SSRI’s or SNRI’s: Potential for Serotonin Syndrome


    Tramadol with ssri s or snri s criteria paragraph l.jpg

    Tramadol with SSRI’s or SNRI’sCriteria Paragraph

    • Tramadol (Ultram®) is a centrally acting synthetic opioid which also inhibits the reuptake of both serotonin and norepinephrine. Therefore, serotonin syndrome can occur when tramadol is used concomitantly with serotonergic drugs such as Selective Serotonin Reuptake Inhibitors (SSRIs) [examples: citalopram, escitalopram, fluoxetine, paroxetine, and sertraline] and Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) [examples: venlafaxine, duloxetine and desvenlafaxine]. During a recent review, it was noted that your patient, Recipient Name, is receiving tramadol and a SSRI or SNRI. The specific SSRI or SNRI product is noted in the attached profile. Please review the attached profile and monitor this patient for potential serotonin syndrome and adjust medications if clinically appropriate (e.g. use a different analgesic agent). Please refer to the attached educational leaflet for signs and symptoms of serotonin syndrome as well as a listing of additional drugs that can precipitate serotonin syndrome.


    Tramadol with ssri s or snri s response detail as of 3 31 2011 l.jpg

    Tramadol with SSRI’s or SNRI’s: Response detail as of 3/31/2011:

    • Note that providers may choose more than one selection per response.

      • Reviewed and do not believe adjustment is needed15

      • Reviewed and have or will modify the treatment4

      • Attempted to modify therapy unsuccessfully3

      • Information clinically useful: plan to monitor10

      • Will use this information in care of future patients8

      • Not my patient, never has been2

      • Previously saw this pt, but no longer in my care5

      • Patient under my care, but not seen recently3


    Tramadol with ssri s or snri s response detail as of 3 31 2011 continued l.jpg

    Tramadol with SSRI’s or SNRI’s: Response detail as of 3/31/2011 (continued):

    • Extremely useful to my practice3

    • Very useful to my practice7

    • Somewhat useful to my practice5

    • Not useful to my practice4

    • Will discontinue medication2

    • Will change dose3

    • Other5


    Tramadol with ssri s or snri s comments of interest l.jpg

    Tramadol with SSRI’s or SNRI’s: Comments of Interest*

    • Profile ID: 0001584482: I was not aware the patient was on tramadol.

    • Profile ID: 0000022513: Defer long term considerations to patient’s primary provider. I am ER provider for this patient.

      * Profile is in member packet for your review


    Thiazolidinediones l.jpg

    Thiazolidinediones

    • Troglitazone – removed from market 1999 due to adverse hepatic effects

    • Pioglitazone hydrochloride (Actos ®) – initial approval 1999

      • Pioglitazone + metformin (Actoplus Met®, Actoplus Met XR®)

      • Pioglitazone + glimepiride (Duetact ®)

    • Rosiglitazone maleate (Avandia®) – initial approval 1999

      • Rosiglitazone + metformin (Avandamet ®)

      • Rosiglitazone + glimepiride (Avandaryl ®)

        Plasma glucose is lowered through PPAR gamma receptors

      • Liver

      • Heart

      • Adipose tissue

      • Skeletal muscle

      • Kidney vascular and gut endothelial cells


    Tzd adverse effects l.jpg

    TZD Adverse Effects

    • Risk of Heart FailureOR 1.32-2.18

      • Pio and Rosi

    • Risk of EdemaOR 2.26-4.62

      • Pio and Rosi

    • Fractures in WomenOR 2.23

      • Pio and Rosi

    • Increased all-cause or cardiovascular mortality

      • Rosiglitazone

      • No evidence with pioglitazone

      • Some studies suggest reduced risk of all-cause and CV mortality with pioglitazone


    Regulatory decisions on rosiglitazone l.jpg

    Regulatory Decisions on Rosiglitazone

    September 2010

    The FDA required GSK to implement a restricted access program for rosiglitazone and combination products that contain rosiglitazone

    • Labeling changes

    • REMS implementation

    • Cease global marketing and promotion

    • Independent re-assessment of RECORD study

    • Suspension of TIDE study

      European Medicines Agency announced suspension of marketing authorization in Europe


    Risk evaluation and mitigation strategy rems l.jpg

    Risk Evaluation and Mitigation Strategy (REMS)

    Restricted Access (added to labeling 2/4/11)

    • Patients already receiving and benefitting

    • New patients not controlled with other anti-diabetic medications and unable to take or do not wish to use pioglitazone

      Documentation

    • Prescribers: attest and document patient eligibility

    • Patients: consent form acknowledging review and understanding of risks

      REMS to be approved Spring 2011 with implementation within 6 months


    Thiazolidinediones tzds l.jpg

    Thiazolidinediones (TZDs)

    • Safety issues with Avandia® related to increased risk for Cardiovascular Events.

    • “The U.S. Food and Drug Administration announced that it will significantly restrict the use of the diabetes drug Avandia® (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia®.”

    http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm


    Thiazolidinediones tzd s l.jpg

    Thiazolidinediones (TZD’s)

    • Patients were selected for evaluation if there was a paid claim for a TZD within the last three months.

    • 83 patient profiles were evaluated.

    • Letters were sent to 65 prescribers about 63 patients on 3/22/2011.

    • As of 3/31/2011, 29 responses have been received (48% response rate.)

    • See packet for copy of the letter and FDA Drug Safety Communication Insert.


    Tzd concurrent medications l.jpg

    TZD – Concurrent Medications

    Other Concurrent Diabetes Medications

    Monotherapy11

    1 other29

    2 other17

    3 other9

    Specific Drugs Used in Combo with Avandia®

    Metformin48

    Sulfonylurea18

    Insulin 8

    Meglitinide2

    Incretin Mimetic1


    Tzd other observations l.jpg

    TZD – Other Observations

    • Adherence issues noted in 13 patients

    • Number of Prescribers

      • Single49

      • Two13

      • Three4

    • Number of Pharmacies

      • Single62

      • Two4


    Tzd s criteria paragraph l.jpg

    TZD’sCriteria Paragraph

    Your patient, Recipient Name, has received at least one recent prescription for rosiglitazone. The FDA has notified healthcare professionals and patients that information on the cardiovascular risks (including heart attack) of rosiglitazone has been added to the product labeling and patient Medication Guide. This information was first announced by the FDA on September 23, 2010 as part of new restrictions for prescribing and use of this drug.

     In addition to describing the cardiovascular risks, the drug labels for Avandia, Avandamet, and Avandaryl have been revised to state that rosiglitazone and rosiglitazone-containing medicines should only be used:

    - In patients already being treated with these medicines

    - In patients whose blood sugar cannot be controlled with other anti-diabetic medicines and who, after consulting with their healthcare professional, do not wish to use pioglitazone-containing medicines (Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®).

     Please read the attached FDA Drug Safety Communication. A link to the FDA complete safety information is included below.

    http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm


    Tzd s response detail as of 3 31 2011 l.jpg

    TZD’s: Response detail as of 3/31/2011:

    • Note that providers may choose more than one selection per response.

      • Reviewed and have or will modify the treatment4

      • Attempted to modify therapy unsuccessfully4

      • Information clinically useful: plan to monitor2

      • Previously saw this pt, but no longer in my care3

      • Very useful to my practice2

      • Somewhat useful to my practice2

      • Will change dose1


    Tzd s comments of interest l.jpg

    TZD’s: Comments of Interest*

    • Profile ID: 0001642778: I am already complying with the above and am no longer prescribing Avandia®.

    • Note that prescriber also wrote in next to number 8 that medication was reordered on January 26, 2011

      * Profile is in member packet for your review


    Ppi s long term use l.jpg

    PPI’s: Long Term Use

    • There are multiple risks associated with long term Proton Pump Inhibitor (PPI) use.

    • Patients were selected for evaluation if they had at least 8 claims for a PPI over the six month period.

    • Profiles are under development.

    • See packet for copy of the letter and Educational Information Handout*


    Ppi s long term use38 l.jpg

    PPI’s: Long Term Use

    • Risk of Fracture:  On May 25, 2010, the FDA revised the prescription label for the proton pump inhibitor (PPI) class of drugs to include new safety information about a possible increased risk of fractures of the hip, wrist, and spine with the use of these medications. There is an associated 25% increase in overall fractures and a 47% increase in spinal fractures in postmenopausal women. 


    Ppi s long term use39 l.jpg

    PPI’s: Long Term Use

    • Hypomagnesemia: The FDA has also issued a statement warning that PPIs taken for prolonged periods of time (in most cases, longer than one year) may also cause low serum magnesium levels.  Low serum magnesium levels can lead to muscle spasm, irregular heartbeat, and convulsions. 

    • Enteric infections: Reduction in acidity may promote bacterial colonization of the gastrointestinal tract which may result in clostridium difficile colitis or bacterial gastroenteritis.


    Ppi s long term use40 l.jpg

    PPI’s: Long Term Use

    • Community-acquired pneumonia: Reduction in acidity may allow ingested pathogens to colonize the stomach with subsequent translocation which increases the incidence of community-acquired pneumonias.


    Slide41 l.jpg

    PPI’s: The review criteria was for 8 or more fills within a six month period. Considered doses above the FDA approved dose for GERD as high as listed in table.

    *Zegerid® not payable by Idaho Medicaid


    Ppi s l.jpg

    PPI’s

    Criteria Paragraph

    • During a retrospective drug utilization review, it was noted that your patient, «MemberName», has received  8 or more fills for a PPI over the 6 month review period.  The FDA has recently revised the prescription label for the proton pump inhibitor (PPI) class of drugs to include new safety information about a possible increased risk of fractures of the hip, wrist, and spine and may also cause low serum magnesium levels. The FDA recommends that when healthcare professionals prescribe PPI's, they should utilize the lowest dose and shortest duration of therapy to adequately treat the patient's condition.


    Ppi s findings upon review l.jpg

    PPI’s: Findings Upon Review:


    Ppi s findings upon review44 l.jpg

    PPI’s: Findings Upon Review:

    • Four participants < 50 years of age were previously denied twice daily therapy

      • three are now receiving two PPIs

      • one is now receiving two PPIs and an H2 antagonist

    • Three participants over 49 years of age are receiving one PPI at GERD dosing


    Slide45 l.jpg

    Investigate issues of low dose atypical antipsychotics being used for sleepSpecific Aim 1: Among Medicaid beneficiaries with a mental illness, compare utilization trends of newer sedative hypnotics, alone and in combination with other psychotropics, across three state Medicaid programs from 2003-2008.Specific Aim 2: Examine the effects of prescription access policies on the utilization of newer sedative hypnotics, pre-to-post policy implementation in each state, and potential substitutions to other psychotropic drugs such as low dose atypical antipsychotics.Specific Aim 3: Compare the impact of implementing prescription access restriction policies on overall prescription drug expenditures and service utilization expenditures among Medicaid beneficiaries with a mental illness diagnosis, pre- and post-policy implementation.Specific Aim 4: Compare changes in use of sleep aids (atypical antipsychotics and/or newer sedative hypnotics) attributable to changes in drug policy between people with and without documented mental illness.NIMH Study Specific Aims

    • Specific Aim 1: Among Medicaid beneficiaries with a mental illness, compare utilization trends of newer sedative hypnotics, alone and in combination with other psychotropics, across three state Medicaid programs from 2003-2008.Specific Aim 2: Examine the effects of prescription access policies on the utilization of newer sedative hypnotics, pre-to-post policy implementation in each state, and potential substitutions to other psychotropic drugs such as low dose atypical antipsychotics.Specific Aim 3: Compare the impact of implementing prescription access restriction policies on overall prescription drug expenditures and service utilization expenditures among Medicaid beneficiaries with a mental illness diagnosis, pre- and post-policy implementation.Specific Aim 4: Compare changes in use of sleep aids (atypical antipsychotics and/or newer sedative hypnotics) attributable to changes in drug policy between people with and without documented mental illness.


    Proposed studies for next quarter l.jpg

    Proposed Studies for Next Quarter:

    • Analysis of Auto Refill Practice*

    • Atypical Antipsychotics: Impact of P&T Recommendations

    • Colchicine Usage

      • Place in Therapy for Treatment of Gout

    • High Dose Utilization Through Multiple Dosage Strengths

      • Oxycodone

      • Atypical Antipsychotics

    • Injectable Antipsychotics

    All information based on Idaho Medicaid Pharmacy Data 1stQuarter 2011 (1/1/11-3/31/11) unless otherwise indicated.


    Auto refill practices l.jpg

    Auto Refill Practices

    Some pharmacies are instituting Auto Refill policies which allow them to automatically dispense refills based on days since last fill

    • Issues

      • Potential for stockpiling

      • Potential for continued fill of discontinued medications

      • Increase cost/waste


    Atypical antipsychotics p t recommendations l.jpg

    Atypical AntipsychoticsP&T Recommendations

    • Approved for diagnosis per FDA indications or off-label indications with supporting evidence-based literature.

    • All patients receiving at least 90 days of therapy for the past 120 days as of implementation date will be grandfathered. No criteria for diagnosis required.

    • No PDL requirements for patients with schizophrenia and related psychosis.

    • Bipolar, major depression adjunctive, autism and other designated acceptable diagnoses will require failure of a preferred agent for designated non-preferred agents.

    • Age, dose and quantity per labeling information on all drugs.

    • If the medical diagnosis and required drug history have been submitted as prior claims then the prescription will auto-approve at point of sale. i.e. No written PA required.


    Atypical antipsychotics p t recommendations49 l.jpg

    Atypical AntipsychoticsP&T Recommendations


    Atypical antipsychotics p t recommendations continued l.jpg

    Atypical AntipsychoticsP&T Recommendations (continued)

    • Adherence Rates


    Atypical antipsychotics p t recommendations continued51 l.jpg

    Atypical AntipsychoticsP&T Recommendations (continued)

    • Adherence Rates


    Atypical antipsychotics p t recommendations continued52 l.jpg

    Atypical AntipsychoticsP&T Recommendations (continued)

    • Adherence Rates


    Atypical antipsychotics p t recommendations53 l.jpg

    Atypical AntipsychoticsP&T Recommendations

    All information based on Idaho Medicaid Pharmacy Data 1stQuarter 2011 (1/1/11-3/31/11).


    Gout treatment colchicine s place in therapy l.jpg

    Gout TreatmentColchicine’s Place in Therapy

    • Acute Gout Attacks –

      • NSAIDS and/or corticosteroids can be used for the management of an acute gout attack.

    • Management of Chronic Gout –

      • Allopurinol is the drug of choice to lower serum uric acid and does not require prior authorization.

      • Uloric® will be approved for payment only after (1) continuation of gout attacks after three months of allopurinol therapy at a therapeutic dose, (2) serum urate levels > 6mg/dl after three months of allopurinol therapy at a therapeutic dose, or (3) documented intolerance to allopurinol. To prevent an acute attack as a result of starting allopurinol, low dose NSAID (e.g. naproxen 250mg twice daily) or prophylactic Colcrys® can be used if there are no contra-indications.

      • Probenecid increases uric acid excretion and does not require prior authorization.


    Gout treatment colchicine s place in therapy55 l.jpg

    Gout TreatmentColchicine’s Place in Therapy

    • Utilization Overview

    All information based on Idaho Medicaid Pharmacy Data 1stQuarter 2011 (1/1/11-3/31/11).


    Slide56 l.jpg

    High Dose Oxycodone Long ActingSix recipients received more than one strength of LA Oxycodone during Jan, Feb, Mar 2011

    All information based on Idaho Medicaid Pharmacy Data 1stQuarter 2011 (1/1/11-3/31/11).


    Slide57 l.jpg

    High Dose Atypical Antipsychotics377 recipients received multiple doses of the same atypical antipsychotic during Jan, Feb, Mar 2011

    All information based on Idaho Medicaid Pharmacy Data 1stQuarter 2011 (1/1/11-3/31/11).


    Injectable atypical antipsychotics invega sustenna and risperdal consta l.jpg

    Injectable Atypical AntipsychoticsInvega® Sustenna® and Risperdal® Consta®

    • Indications

    • Utilization Overview

    *Idaho Medicaid Data 4th Quarter 2010 (10/1/2010-12/31/2010)


    Injectable atypical antipsychotics invega sustenna and risperdal consta59 l.jpg

    Injectable Atypical AntipsychoticsInvega® Sustenna® and Risperdal® Consta®

    • Goal 1:Evaluate Adherence Rates

      • Oral use prior

      • Current adherence

      • For Invega Sustenna – previous adherence on Risperdal Consta

      • Ensure not receiving oral therapy in addition to injectable

  • Goal 2:Program Integrity

    • Ensure doses dispensed by the pharmacy are actually administered

    • Compare drug profiles, medication administration records and time period


  • Injectable atypical antipsychotics l.jpg

    Injectable Atypical Antipsychotics

    Study Responsibilities

    • MMA:

      • Patient list

      • Pharmacy and Prescriber identification

    • Program Integrity:

      • Request and obtain the medication administration records and the progress notes

      • Take action on any identified fraud or billing irregularities

    • Medicaid Pharmacy Staff

      • Compile and analyze treatment for each patient

      • Present an analysis of the data to DUR Board and P&T Committee

    • DUR Board and P&T Committee

      • Review and interpret results

      • Make Conclusions and Recommendations


    Injectable atypical antipsychotics invega sustenna and risperdal consta61 l.jpg

    Injectable Atypical AntipsychoticsInvega® Sustenna® and Risperdal® Consta®

    • Adherence Rates

    Adherence calculated by evaluating claims for patients receiving multiple claims for the same agent and comparing difference between days’ supply and days between refills.

    *Idaho Medicaid Data 3rd Quarter 2010 (7/1/2010-9/30/2010)


    Prospective dur report l.jpg

    Prospective DUR Report

    • History Errors:

      • DD – drug-to-drug

      • PG – drug to pregnancy

      • TD – therapeutic duplication

      • ER – early refill

      • MC – drug-to-disease

    • Non-History Errors:

      • PA – drug-to-age

      • HD – high dose

      • LD – low dose

      • SX – drug-to-gender


    Slide63 l.jpg

    ProDUR Message Report: December 2010 (for comparison)


    Slide64 l.jpg

    ProDUR Message Report: February 2011


    Top drugs for selected produr type duplicate therapy l.jpg

    Top Drugs for Selected ProDUR Type:Duplicate-Therapy

    • Hydrocodone/APAP with other Hydrocodone/APAP – 2,516 alerts (14.44% of claims for Hydrocodone/APAP)

    • Methylphenidate with other methylphenidate – 1,917 alerts (34.72% of claims for methylphenidate)

    • Quetiapine with other quetiapine – 1,915 alerts (51.41% of claims for quetiapine)

    • Oxycodone/APAP with hydrocodone/APAP – 1,448 alerts (57.57% of claims for oxycodone/APAP)

    • Venlafaxine with other venlafaxine – 1,438 alerts (73.90% of claims for venlafaxine)

    • Bupropion with bupropion – 1,409 alerts (45.61% of claims for bupropion)

    • Hydrocodone/APAP with tramadol – 1,166 alerts (6.69% of claims for bupropion)


    Dur spring newsletter l.jpg

    DUR Spring Newsletter

    • Brainstorm for new topics


    New annual dur report electronic submission l.jpg

    New Annual DUR Report Electronic Submission

    Background

    Each State must submit an annual DUR report that includes

    • Nature and Scope Description

      • Prospective DUR Program

      • Retrospective DUR Program

    • Assessment of Education Program

    • Description of DUR Board Activities

    • Assessment of DUR Program

      • Impact on Quality of Care

      • Cost Savings Generated by Program


    New annual dur report electronic submission68 l.jpg

    New Annual DUR Report Electronic Submission

    Differences from Previous Report

    • New Sections

      • Physician Administered Drugs

      • Generic Policy and Utilization

      • Fraud, Waste and Abuse Detection

      • Innovative Practices

      • E-Prescribing

    • Changes

      • ProDUR focus on early refill and therapeutic duplication and associated override and PA policies

      • Less emphasis on DUR meeting statistics and policies

      • More emphasis on DUR Involvement in programs such as Disease Management and Medication Therapy Management

      • New format and evaluation process for program evaluation and cost savings.


    Medicaid update l.jpg

    Medicaid Update


  • Login